4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
February 2023 in “European Journal of Medical Research” Certain existing drugs, like glycopyrronium and botulinum toxin type A, may help treat excessive sweating.
January 2025 in “Cermin Dunia Kedokteran” Choose anti-epileptic drugs carefully for women of childbearing age to avoid risks during pregnancy.
November 2025 in “Dermatology and Therapy” The drinkable supplement increased hair growth and was safe for women with hair loss.
4 citations
,
January 1989
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
1 citations
,
January 1999 in “The European journal of contraception & reproductive health care” Valette® is an effective birth control pill that also reduces greasy hair and skin.
January 2026 in “http://isrctn.com/” The supplement may improve hair growth and quality in women with mild to moderate hair loss.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
7 citations
,
April 2012 in “Clinical investigation” Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.
Onabotulinumtoxin-A effectively treated a painful scalp condition when other treatments failed.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
June 2025 in “Veterinary Sciences” Oclacitinib effectively treated a diabetic cat's severe skin issues without raising glucose levels, and surgery fixed eyelid fusion.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
Researchers made new compounds that could potentially be developed into anticancer drugs.
January 2018 in “Journal of the American Academy of Dermatology” More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
42 citations
,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
April 2019 in “Journal of the Endocrine Society” Glucocorticoid treatment lowered androgen levels but didn't improve hirsutism or ovulation and caused weight gain.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
September 2023 in “Journal of the American Academy of Dermatology” ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.
2 citations
,
April 2019 in “Медицинский совет” Combined oral contraceptives improve skin, hormone levels, and quality of life in women with PCOS.
October 2009 in “Reactions Weekly” A woman developed lupus after taking hydroxyurea for two years.
November 2025 in “Journal of Pharmaceutical Research International” Ustekinumab and vedolizumab can help some ulcerative colitis patients with hair regrowth, but results vary.
October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana” PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
January 2025 in “Dusunen Adam The Journal of Psychiatry and Neurological Sciences”
January 2020 in “Current trends in diagnosis & treatment” The review suggests doctors should carefully weigh risks and benefits of off-label drug use, involve patients in decisions, and calls for better regulations and monitoring.
19 citations
,
June 1997 in “The Journal of Clinical Endocrinology & Metabolism” The treatment successfully lowered testosterone levels and reduced symptoms.